Back to search

Article

Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current Evidence

2026-02-09

Abstract excerpt

<title>Abstract</title> <p>Background Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for the management of type 2 diabetes, metabolic syndrome, and obesity. Concerns regarding its potential association with thyroid cancer, particularly medullary thyroid carcinoma have emerged, although current human evidence remains inconclusive. Reports of papillary thyroid carcinoma (PTC) fo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d1a9be31-15d1-5981-aa7a-c97d03c3bb34
DOI
10.21203/rs.3.rs-8344892/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current EvidenceDOI 10.21203/rs.3.rs-8344892/v1
Select a neighboring publication to make it the new centre.